Use this page to review federal contract obligations for PSC 6550 (IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS) for last 10 years. The analysis is based on FPDS award-action data.
PSC Code
PSC 6550 Federal Contract Obligations (Last 10 Years)
This page summarizes federal contract obligations for PSC 6550 (IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS) for last 10 years, including award volume and market trend context.
All figures on this page are based on FPDS award-action obligation data for completed calendar years only within the last 10 years analysis window.
PSC Code
6550
PSC Description
IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
Total Obligated
4.41 billion
4,413,511,987.34
Award Actions
51,640
Average Action Value
85,466.92
About PSC 6550 federal contract activity
This page summarizes last 10 years of federal contract activity associated with PSC 6550 (IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS). Based on the current FPDS Query dataset, this category shows 4.41 billion in visible obligations across 51,640 award actions, with an average action value of 85,466.92. This view is designed to help users quickly understand scale, buyer concentration, contractor concentration, and overall market direction before moving into deeper procurement analysis.
Agency demand and leading federal buyers
Demand for PSC 6550 (IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS) appears concentrated among a relatively small group of federal buyers over the last 10 years. The visible agency ranking is led by DEPT OF THE ARMY, with 1.40 billion in obligations, followed by VETERANS AFFAIRS, DEPARTMENT OF. This kind of concentration is useful context for business development, bid targeting, and understanding where the strongest federal demand appears to sit.
Vendor concentration and leading contractors
The vendor distribution helps show which contractors capture the largest visible share of obligations in PSC 6550 (IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS) over the last 10 years. The current ranking is led by ASTRAZENECA PHARMACEUTICALS LP, with 1.11 billion in obligations, followed by ABBOTT RAPID DX NORTH AMERICA, LLC. This gives users a practical view of the competitive landscape and the visible concentration at the top of the market.
Annual contract trend over the analysis window
The annual trend table provides a year-based view of how visible obligations and award actions have evolved for PSC 6550 (IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS) across the last 10 years, from 2016 through 2025. This is useful for spotting periods of expansion, relative stability, or softening activity in this federal market segment.
How to interpret this page
The tables and trend blocks on this page are generated from FPDS-derived procurement records prepared offline for fast public delivery. They are intended to give a practical summary of category-scale obligations, top buying agencies, leading vendors, and visible year-over-year movement within last 10 years. Users who need deeper filtering, custom SQL, or cross-market comparison can continue the analysis directly inside FPDS Query.
Top Agencies
SELECT
agency_id,
agency_name,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
content__award__purchaserInformation__contractingOfficeAgencyID AS agency_id,
anyHeavy(content__award__purchaserInformation__contractingOfficeAgencyID__name) AS agency_name,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__productOrServiceInformation__productOrServiceCode = '6550'
AND content__award__purchaserInformation__contractingOfficeAgencyID IS NOT NULL
AND content__award__purchaserInformation__contractingOfficeAgencyID != ''
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 10 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY agency_id
)
ORDER BY total_obligated DESC
LIMIT 10| Agency ID | Agency Name | Total Obligated | Readable | Award Actions |
|---|---|---|---|---|
| 2100 | DEPT OF THE ARMY | 1,401,225,327.46 | 1.40 billion | 4,963 |
| 3600 | VETERANS AFFAIRS, DEPARTMENT OF | 1,070,892,456.82 | 1.07 billion | 13,169 |
| 7505 | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE | 881,000,682.42 | 881.00 million | 46 |
| 97AS | DEFENSE LOGISTICS AGENCY | 360,154,543.10 | 360.15 million | 21,266 |
| 5700 | DEPT OF THE AIR FORCE | 183,454,683.58 | 183.45 million | 1,328 |
| 7527 | INDIAN HEALTH SERVICE | 126,935,616.58 | 126.94 million | 2,307 |
| 1700 | DEPT OF THE NAVY | 113,742,655.61 | 113.74 million | 3,453 |
| 97DH | DEFENSE HEALTH AGENCY (DHA) | 98,557,725.71 | 98.56 million | 1,189 |
| 7529 | NATIONAL INSTITUTES OF HEALTH | 60,207,894.35 | 60.21 million | 1,454 |
| 7524 | FOOD AND DRUG ADMINISTRATION | 29,048,870.01 | 29.05 million | 441 |
Insight
PSC 6550 (IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS) appears to be concentrated among a relatively small group of major buying agencies over the last 10 years. The visible ranking is led by DEPT OF THE ARMY, followed by VETERANS AFFAIRS, DEPARTMENT OF, which suggests that agency demand in this category is not evenly distributed.
Top Vendors
SELECT
vendor_name,
cage_code,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
content__award__vendor__vendorHeader__vendorName AS vendor_name,
ifNull(anyHeavy(content__award__vendor__vendorSiteDetails__entityIdentifiers__cageCode), '') AS cage_code,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__productOrServiceInformation__productOrServiceCode = '6550'
AND content__award__vendor__vendorHeader__vendorName IS NOT NULL
AND content__award__vendor__vendorHeader__vendorName != ''
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 10 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY
vendor_name,
content__award__vendor__vendorSiteDetails__entityIdentifiers__cageCode
)
ORDER BY total_obligated DESC
LIMIT 10| Vendor | CAGE Code | Total Obligated | Readable | Award Actions |
|---|---|---|---|---|
| ASTRAZENECA PHARMACEUTICALS LP | 36WK2 | 1,107,934,203.08 | 1.11 billion | 12 |
| ABBOTT RAPID DX NORTH AMERICA, LLC | 5C4F2 | 366,528,371.34 | 366.53 million | 213 |
| ROCHE DIAGNOSTICS CORPORATION | 51169 | 288,086,798.05 | 288.09 million | 2,152 |
| OSANG LLC | 969A8 | 237,000,000.00 | 237.00 million | 4 |
| CEPHEID | 07YE7 | 208,332,679.24 | 208.33 million | 1,264 |
| BECTON, DICKINSON AND COMPANY | 22790 | 179,408,331.45 | 179.41 million | 481 |
| RAYTHEON COMPANY | 05716 | 171,163,890.42 | 171.16 million | 4 |
| ACCESS BIO, INC. | 3CNE1 | 135,454,000.00 | 135.45 million | 6 |
| QUIDEL CORPORATION | 0TH42 | 121,851,040.80 | 121.85 million | 83 |
| ABBOTT LABORATORIES | 33110 | 107,579,312.05 | 107.58 million | 678 |
Insight
Within PSC 6550 (IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS), visible obligations over the last 10 years appear concentrated among a relatively small set of leading vendors. ASTRAZENECA PHARMACEUTICALS LP ranks first, followed by ABBOTT RAPID DX NORTH AMERICA, LLC, which helps define the current competitive landscape in this category.
Annual Trend
SELECT
year,
total_obligated,
award_count,
formatReadableQuantity(total_obligated) AS total_obligated_readable
FROM
(
SELECT
toYear(parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate)) AS year,
sum(content__award__dollarValues__obligatedAmount) AS total_obligated,
count() AS award_count
FROM fpds.data
WHERE
contract_type = 1
AND content__award__productOrServiceInformation__productOrServiceCode = '6550'
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) >= toStartOfYear(now()) - INTERVAL 10 YEAR
AND parseDateTimeBestEffortOrNull(content__award__relevantContractDates__signedDate) < toStartOfYear(now())
GROUP BY year
)
ORDER BY year DESC| Year | Total Obligated | Readable | Award Actions |
|---|---|---|---|
| 2025 | 347,203,699.79 | 347.20 million | 5,172 |
| 2024 | 215,712,226.83 | 215.71 million | 5,694 |
| 2023 | 348,075,211.97 | 348.08 million | 5,173 |
| 2022 | 1,934,165,109.83 | 1.93 billion | 5,229 |
| 2021 | 594,325,431.43 | 594.33 million | 5,555 |
| 2020 | 378,375,704.05 | 378.38 million | 5,758 |
| 2019 | 141,426,399.77 | 141.43 million | 5,101 |
| 2018 | 163,149,363.15 | 163.15 million | 4,961 |
| 2017 | 149,038,932.42 | 149.04 million | 4,965 |
| 2016 | 142,039,908.10 | 142.04 million | 4,032 |
Insight
The annual trend shows how obligations in PSC 6550 (IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS) moved across the last 10 years, from 2016 through 2025. This helps users judge whether visible contract activity in this category appears stable, rising, or easing over time.
Use FPDS Query for deeper PSC analysis
Explore federal procurement data with custom SQL, fast filtering, and deeper PSC analysis across agencies, vendors, and annual trends.
Continue from this last 10 years view into full FPDS Query workflows with deeper filtering, custom SQL, saved queries, and broader market comparison.